FindTrial
Sign In

Comparison of efficacy and safety of famciclovir and valacyclovir in patients with Herpes zoster.

Comparison of efficacy, cost effectiveness and safety of famciclovir and valacyclovir in Herpes zoster â?? a randomized controlled double blind parallel arm study. - FaVer study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/05/005765
Enrollment
70
Registered
2015-05-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Herpes zoster

Interventions

Intervention1: Famciclovir: 500 mg 3 times daily for 7 days orally Control Intervention1: valacyclovir: 1000 mg 3 times daily for 7 days orally

Sponsors

Jawaharlal Institute of Postgraduate Medical Education Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients attending Dermatology OPD, JIPMER diagnosed with uncomplicated herpes zoster presenting within 72 hrs of onset of rash will be recruited for the study based on eligibility criteria.

Exclusion criteria

Exclusion criteria: Patients with complications of Herpes zoster, including ocular involvement, severe disseminated infections, motor neuropathies, encephalitis or cerebrovascular complications. Pregnant women or lactating mothers Patients with concurrent malignancy receiving chemotherapy Patients with autoimmune diseases and or on immunosuppressants HIV sero-positive Renal impairment Hepatic impairment

Design outcomes

Primary

MeasureTime frame
Reduction in pain using visual analogue scale scoreTimepoint: Day 0 and day 8—

Secondary

MeasureTime frame
time taken for the full crusting of the lesionsTimepoint: Day 0 and day 8—

Countries

India

Contacts

Public ContactDr S Sandhiya

JIPMER

sandhiyaselvarajan@gmail.com9443492922

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026